Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma

Annals of Surgery

Volumn 250, Issue 6, 2009, Pages 950-956

  Murakami, Yoshiaki ^a   Uemura, Kenichiro ^a   Sudo, Takeshi ^a   Hayashidani, Yasuo ^a   Hashimoto, Yasushi ^a   Nakamura, Hiroyuki ^a   Nakashima, Akira ^a   Sueda, Taijiro ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; GEMCITABINE;

ADJUVANT THERAPY; ADVANCED CANCER; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; LEUKOPENIA; LIVER RESECTION; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; THROMBOCYTOPENIA;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BILIARY TRACT NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HEPATECTOMY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; MALE; OXONIC ACID; PANCREATICODUODENECTOMY; POSTOPERATIVE CARE; SURVIVAL RATE; TEGAFUR; TIME FACTORS; TREATMENT OUTCOME;

EID: 73449122261     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181b0fc8b     Document Type: Article

References (54)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Okusaka T. Chemotherapy for biliary tract cancer in Japan. Semin Oncol. 2002;29:51-53.
3. Nagino M, Kamiya J, Nishio H, et al. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Ann Surg. 2006;243:364-372.
4. Yoshida T, Matsumoto T, Sasaki A, et al. Prognostic factors after pancre-atoduodenectomy with extended lymphadenectomy for distal bile duct cancer. Arch Surg. 2002;137:69-73.
5. Shimizu H, Kimura F, Yoshidome H, et al. Aggressive surgical approach for stage IV gallbladder carcinoma based on Japanese Society of Biliary Surgery classification. J Hepatobiliary Pancreat Surg. 2007;14:358-365.
6. Kim RD, Kundhal PS, McGilvray ID, et al. Predictors of failure after pancreaticoduodenectomy for ampullary carcinoma. J Am Coll Surg. 2006; 202:112-119.
7. Brown KM, Tompkins AJ, Yong S, et al. Pancreaticoduodenectomy is curative in the majority of patients with node-negative ampullary cancer. Arch Surg. 2005;140:529-533.
8. Duffy JP, Hines OJ, Liu JH, et al. Improved survival for adenocarcinoma of the ampulla of Vater: fifty-five consecutive resections. Arch Surg. 2003;138: 941-950.
9. Sudo T, Murakami Y, Uemura K, et al. Prognostic impact of perineural invasion following pancreatoduodenectomy with lymphadenectomy for am-pullary carcinoma. Dig Dis Sci. 2008;53:2281-2286.
10. Murakami Y, Uemura K, Hayashidani Y, et al. Pancreatoduodenectomy for distal cholangiocarcinoma: prognostic impact of lymph node metastasis. World J Surg. 2007;31:337-342. (Pubitemid 46183520)
11. Sakamoto Y, Kosuge T, Shimada K, et al. Prognostic factors of surgical resection in middle and distal bile duct cancer: an analysis of 55 patients concerning the significance of ductal and radial margins. Surgery. 2005;137: 396-402.
12. Kayahara M, Nagakawa T, Ohta T, et al. Role of nodal involvement and the periductal soft-tissue margin in middle and distal bile duct cancer. Ann Surg. 1999;229:76-83.
13. Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;22:463-475.
14. Sasaki R, Itabashi H, Fujita T, et al. Related Significance of extensive surgery including resection of the pancreas head for the treatment of gallbladder cancer-from the perspective of mode of lymph node involvement and surgical outcome. World J Surg. 2006;30:36-42.
15. Yamaguchi R, Nagino M, Oda K, et al. Perineural invasion has a negative impact on survival of patients with gallbladder carcinoma. Br J Surg. 2002;89:1130-1136.
16. Chijiiwa K, Tanaka M. Carcinoma of the gallbladder: an appraisal of surgical resection. Surgery. 1994;115:751-756.
17. Rea DJ, Munoz-Juarez M, Farnell MB, et al. Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients. Arch Surg. 2004;139:514-525.
18. Hemming AW, Reed AI, Fujita S, et al. Surgical management of hilar cholangiocarcinoma. Ann Surg. 2005;241:693-702.
19. Nimura Y, Kamiya J, Kondo S, et al. Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience. J Hepatobiliary Pancreat Surg. 2000;7:155-162.
20. Miyazaki M, Ito H, Nakagawa K, et al. Parenchyma-preserving hepatectomy in the surgical treatment of hilar cholangiocarcinoma. J Am Coll Surg. 1999;189:575-583.
21. Todoroki T, Ohara K, Kawamoto T, et al. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys. 2000;46:581-587.
22. Serafini FM, Sachs D, Bloomston M, et al. Location, not staging, of cholan-giocarcinoma determines the role for adjuvant chemoradiation therapy. Am Surg. 2001;67:839-844.
23. Kresl JJ, Schild SE, Henning GT, et al. Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. Int J Radiat Oncol Biol Phys. 2002;52:167-175.
24. Takada T, Amano H, Yasuda H, et al. Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multi-center prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95:1685-1695.
25. Nakeeb A, Tran KQ, Black MJ, et al. Improved survival in resected biliary malignancies. Surgery. 2002;132:555-564.
26. Gerhards MF, van Gulik TM, González González D, et al. Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg. 2003;27:173-179.
27. Kim S, Kim SW, Bang YJ, et al. Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys. 2002;54:414-419.
28. Sikora SS, Balachandran P, Dimri K, et al. Adjuvant chemo-radiotherapy in ampullary cancers. Eur J Surg Oncol. 2005;31:158-163.
29. Czito BG, Hurwitz HI, Clough RW, et al. Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience. Int J Radiat Oncol Biol Phys. 2005;62: 1030-1034.
30. Sagawa N, Kondo S, Morikawa T, et al. Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma. Surg Today. 2005;35:548-552.
31. Bhatia S, Miller RC, Haddock MG, et al. Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 2006;66:514-519.
32. Hughes MA, Frassica DA, Yeo CJ, et al. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys. 2007;68:178-182.
33. Cheng Q, Luo X, Zhang B, et al. Predictive factors for prognosis of hilar cholangiocarcinoma: postresection radiotherapy improves survival. Eur J Surg Oncol. 2007;33:202-207.
34. Krishnan S, Rana V, Evans DB, et al. Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater. Int J Radiat Oncol Biol Phys. 2008;70:735-743.
35. Nelson JW, Ghafoori AP, Willett CG, et al. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2009;73:148-153.
36. Murakami Y, Uemura K, Hayasidani Y, et al. Indication for postoperative adjuvant therapy in biliary carcinoma based on analysis of recurrence and survival after surgical resection. Dig Dis Sci. 2009;54:1360-1364.
37. Penz M, Kornek GV, Raderer M, et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol. 2001;12:183-186.
38. Tsavaris N, Kosmas C, Gouveris P, et al. Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs. 2004;22: 193-198.
39. Okusako T, Ishii H, Funakoshi A, et al. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol. 2006;57:647-653.
40. Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7:548-557.
41. Nakamura K, Yamaguchi T, Ishihara T, et al. Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer. 2006;94:1575-1579.
42. Murakami Y, Uemura K, Sudo T, et al. Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma. Am J Surg. 2008;195:757-762.
43. Sobin LH, Wittekind C, eds. International Union Against Cancer (UICC): TNM Classification of Malignant Tumours. 6th ed. New York, NY: Wiley-Liss; 2002.
44. Beger HG, Treitschke F, Gansauge F, et al. Tumor of the ampulla of Vater: experience with local or radical resection in 171 consecutively treated patients. Arch Surg. 1999;134:526-532.
45. Suzuki M, Unno M, Oikawa M, et al. Surgical treatment and postoperative outcomes for middle and lower bile duct carcinoma in Japan-experience of a single institute. Hepatogastroenterology. 2000;47:650-657.
46. Tsukada K, Hatakeyama K, Kurosaki I, et al. Outcome of radical surgery for carcinoma of the gallbladder according to the TNM stage. Surgery. 1996; 120:816-821.
47. Jarnagin WR, Ruo L, Little SA, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98:1689-1700.
48. Hasegawa S, Ikai I, Fujii H, et al. Surgical resection of hilar cholangiocar-cinoma: analysis of survival and postoperative complications. World J Surg. 2007;31:1256-1263.
49. Koeberle D, Saletti P, Borner M, et al. Patient-reported outcomes of patients with advanced biliary cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2008;26:3702-3708.
50. Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol. 2005; 23:2332-2338.
51. Cho JY, Paik YH, Chang YS, et al. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer. 2005;104:2753-2758.
52. Ueno H, Okusaka T, Ikeda M, et al. Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer. 2004;91:1769-1774.
53. Kim YJ, Im SA, Kim HG, et al. A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer. Ann Oncol. 2008;19:99-103.
54. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267-277.